Our top pick for
Cronos Australia is a pharmaceuticals business based in Australia. Cronos Australia shares (CAU) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Cronos Australia has a trailing 12-month revenue of around $67 million. If you're looking to buy shares, check out the steps below.
|52-week range||$0.315 - $0.72|
|50-day moving average||$0.5683|
|200-day moving average||$0.498|
|Dividend yield||$0.01 (1.85%)|
|Earnings per share (TTM)||$0.01|
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 year (2022-11-29)||-41.94%|
|2 years (2021-11-29)||84.62%|
|3 years (2020-11-27)||200.00%|
Valuing Cronos Australia stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cronos Australia's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cronos Australia's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 54x. In other words, Cronos Australia shares trade at around 54x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cronos Australia's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.1 million (£0.0 million).
The EBITDA is a measure of a Cronos Australia's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$67 million|
|Operating margin TTM||14.81%|
|Gross profit TTM||$25.4 million|
|Return on assets TTM||24%|
|Return on equity TTM||40.03%|
|Market capitalisation||$300.5 million|
TTM: trailing 12 months
Dividend payout ratio: 100% of net profits
Recently Cronos Australia has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.85% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Cronos Australia shareholders could enjoy a 1.85% return on their shares, in the form of dividend payments. In Cronos Australia's case, that would currently equate to about A$0.01 per share.
Cronos Australia's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 16 September 2022 (the "ex-dividend date").
Over the last 12 months, Cronos Australia's shares have ranged in value from as little as $0.315 up to $0.72. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Cronos Australia's is 0.0683. This would suggest that Cronos Australia's shares are less volatile than average (for this exchange).
Cronos Australia Limited engages in the sale and distribution of medicinal cannabis products, and operation of medicinal cannabis clinic businesses in Australia and Asia. It operates through three segments: Medical, Clinics, and Consumer. The company sells its medicinal cannabis products under the Adaya brand, as well as through online marketplace platform. It also offers hemp seed oil personal care consumer products under the Bathing Shed brand; and CBD-based products under the FCTR and Saiph brands. The company was incorporated in 2018 and is based in South Yarra, Australia.
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Microsoft shares from in Australia.
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.